Pharma competitive intelligence servicesBeyond monitoring: intelligence that drives decisions
We run the full CI cycle for biopharma CI and brand teams, connecting evidence to implications, and implications to action.
Three intelligence engines, one decision-ready view
Always-on monitoring, question-led research and event-driven congress coverage, organized around your KITs and KIQs.
Secondary CI
Maintain strategic visibility
- Competitor, clinical and regulatory monitoring
- Alerts, trackers and forward watchpoints
- Competitive landscapes and trial mapping
- Earnings and investor-call implications
- Monthly and quarterly CI reports
Primary CI
Test the critical unknowns
- Expert, KOL, payer and field interviews
- Hypothesis testing and triangulation
- Confidence-rated view of competitor intent
- Ethically sourced, compliant by design
- Competitive simulations and war games
Conference Intelligence
Capture inflection points
- 20+ congresses: ASCO, ESMO, ASH, ESC, ATS
- Pre-congress KIT/KIQ planning
- On-site and virtual coverage
- Daily highlights and strategic debrief
- Post-congress implications for your brand
We run the full CI cycle, not just monitoring
From the annual CI plan to the tools that run it, while lowering the total cost of intelligence.
Build the annual CI plan
- Priority KITs/KIQs agreed with stakeholders
- Competitor watchlist and key-event calendar
- Deliverable cadence and stakeholder map
Set up the right tools
- Our AI platforms, set up for your KIQs
- Advice on the databases you actually need
- Governed repository from day one
Run the plan all year
- Alerts, debriefs, monthly and quarterly reports
- Congress coverage and primary CI on demand
- Implications for your brand, not just news
Lower the cost of CI
- Standardized AI workflows cut manual effort
- Trim overlapping database subscriptions
- Refresh the plan each year on what was used
↻ Annual cycle: what we learn in execution shapes next year’s plan
We connect evidence to implications, and to action
Technology scales the workflow. Analysts remain accountable for the conclusion.
DETECT
→ SignalsMonitor what matters to your KIQs
VALIDATE
→ EvidenceTriangulate and confidence-rate
INTERPRET
→ InsightRead it in clinical and commercial context
ANTICIPATE
→ ScenariosModel how competitors may respond
ENABLE
→ DecisionsImplications and decision triggers
Most providers stop at monitoring. We deliver all three levels.
News summaries tell you what happened. CI leaders need to know what it means for their asset and what to do next, with a view they can defend in front of leadership.
- Pharma-native judgement: former brand and CI leaders interpret every signal
- Connected evidence: primary, secondary and congress CI, triangulated
- Governed AI delivery: AI adds speed, analysts stay accountable
What happened?
What does it mean for us?
What should we do?
Flexible support, built around your team’s priorities
Start with a single question and scale to a dedicated team as your needs grow.
Project-based
Deep dives, landscapes and congress coverage for a defined question or event.
Ongoing CI support
Continuous monitoring, alerts and monthly or quarterly reports against your CI plan.
Embedded partnership
A dedicated team integrated with your CI function, working as an extension of your team.
Pharma competitive intelligence, answered
What is pharmaceutical competitive intelligence? It is the ethical collection and analysis of information about competitors, pipelines, trials, regulatory events and markets, turned into implications that help biopharma teams decide. AdametNext delivers it through secondary CI, primary CI and conference intelligence, run by a pharma-insider team and accelerated by AI.
What is pharmaceutical competitive intelligence?
Pharmaceutical competitive intelligence (CI) is the ethical collection and analysis of information about competitors, pipelines, clinical trials, regulatory events and market dynamics, translated into implications that help biopharma brand, portfolio and strategy teams make better decisions. At AdametNext, CI runs from detecting signals to validating evidence, interpreting it in clinical and commercial context, anticipating competitor responses and enabling decisions.
What is the difference between secondary CI, primary CI and conference intelligence?
Secondary CI is always-on monitoring of published sources such as trial registries, regulatory updates, earnings calls and company news. Primary CI is question-led research through expert, KOL, payer and field interviews to test critical unknowns. Conference intelligence is event-driven coverage of medical congresses such as ASCO, ESMO, ASH, ESC and ATS, from pre-congress planning to post-congress implications.
Which therapy areas does AdametNext cover?
AdametNext provides competitive intelligence across seven core therapy areas: oncology, immunology, respiratory, neurology, cardiometabolic, rare disease and vaccines.
How does AdametNext use AI in competitive intelligence?
AI speeds the work; analysts own every conclusion. Our proprietary platforms, ADN CI Platform, ConferaIQ and ARISENTIQ, standardize monitoring, conference capture and signal analysis, while pharma-trained analysts review, validate and own every insight we deliver.
How can we engage AdametNext?
Clients work with us in three ways: project-based support for a specific question, ongoing CI support, or an embedded partnership in which we run the full CI cycle with your team, from the annual CI plan to the tools and reporting that deliver it.
Is your competitive intelligence ethical and compliant?
Yes. Our primary CI is ethically sourced and compliant by design, and we have published a practical CI ethics white paper covering secondary research, KOL engagement, conference coverage and vendor due diligence across the US, EU and UK.